Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Michael J. Cork et al.|New England Journal of Medicine|2016Cited by 2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I. Silverberg, Alan Clucas, Andreas Pinter et al.|Journal of Allergy and Clinical Immunology|2019Cited by 268